| Neonatal onset (N = 6) | Early infantile onset (N = 8) | Late-infantile onset (N = 51) | Juvenile onset (N = 42) | Adolescent/adult onset (N = 25) |
---|---|---|---|---|---|
Gender, n (%) female | 3 (50) | 7 (88) | 28 (55) | 25 (60) | 10 (40) |
Age, years: | Â | Â | Â | Â | Â |
At neurological onset | Â | Â | Â | Â | Â |
 na | – | 8 | 50 | 40 | 18 |
 Mean (SD) | – | 1.1 (0.7) | 4.1 (1.2) | 9.4 (2.6) | 24.2 (8.8) |
At diagnosis | Â | Â | Â | Â | Â |
 na | 4c | 7c | 49 | 39 | 24 |
 Mean (SD) | 0.1 (0.1) | 1.3 (1.5) | 4.6 (5.5) | 11.5 (7.4) | 29.3 (9.3) |
At last follow upb | Â | Â | Â | Â | Â |
 na | – | – | 19 | 21 | 17 |
 Mean (SD) | – | – | 11.6 (8.9) | 20.2 (9.0) | 39.5 (9.2) |
At death | Â | Â | Â | Â | Â |
 na | 6 | 8 | 30 | 19 | 8 |
 Mean (SD) | 0.19 (0.22) | 5.6 (2.0) | 13.4 (6.7) | 25.9 (8.9) | 33.7 (6.2) |
Number (%)d with NP-C genetic information | 1 (17) | 8 (100) | 41 (80) | 36 (86) | 16 (64) |
Number (%)d treated with miglustat | – | 2 (25) | 17 (33) | 20 (48) | 12 (48) |